Mashiah J, et al. - The clinical efficacy and safety profile of topical pimecrolimus cream for the treatment of cutaneous mastocytosis (CM) were assessed by the experts. They noted that out of the treated lesions, 26.7% disappeared and 67% faded or developed postinflammatory hyperpigmentation. Among the papular lesions, 16.4% demonstrated partial flattening and 47% developed into macular lesions. Results demonstrated that in the treatment of CM, topical therapy with pimecrolimus 1% cream ought to be considered.